Primary endpoints of the study were 3-month safety (defined as proportion difference in persistent Clavien grade 1 event or grade 2 or higher event by month 3) and 6-month efficacy (defined in IPSS at 6 months. Both were tested for non-inferiority. Aquablation was found to be superior in terms of primary safety, ejaculatory function postoperatively, incontinence severity; it was non-inferior in terms of primary efficacy, and it resulted in statistically significantly greater urine flow. Upon subgroup analysis of patients with >50g prostate size, aquablation was superior in regard to primary safety (Clavien complications: 19% Aquablation vs 43% TURP, p<0.01) and efficacy (IPSS drop: 17 points Aquablation vs 13 points TURP, p=0.01). Furthermore, the resection time for aquablation (4 minutes) was significantly shorter than TURP (27 minutes), and was independent of gland volume.
This promising technology may result in a substantially improved method for surgically treating patients with symptomatic BPH.
Authors: Claus Roerhborn, MD
Affiliation: Department of Urology, University of Texas Southwestern
Written By: Shoaib Safiullah, MS4 for UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA